VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities


VaxTRIALS has been acquired by Emmes, a portfolio company of New Mountain Capital, to add a new Latin America base and vaccine research depth.


To effectively introduce vaccines to the market, sponsors depend on specialized vaccine-focused research sites to orchestrate clinical trials. These sites offer comprehensive support throughout the process, managing tasks ranging from enlisting participants and ensuring regulatory adherence to gathering data, all within tighter schedules compared to conventional trials. As the worldwide vaccine market is projected to surpass $65 billion by 2026, Contract Research Organizations (CROs) are enhancing their proficiency in vaccines to cater to the escalating need and capitalizing on the trend of outsourcing the management of clinical research sites.

Since 2012, VaxTRIALS has been involved in over 50 vaccine-related clinical, epidemiological and health economics trials throughout the Latin American region. They are the largest vaccine focused CRO in the region with an active presence in 10+ countries. This market leading position made VaxTRIALS the ideal acquisition for Emmes to expand its vaccine clinical trial CRO capabilities.

Crosstree’s Role

Crosstree’s expertise in the CRO industry, and deep understanding of VaxTRIALS’ unique value proposition helped the firm advise VaxTRIALS in identifying Emmes as the ideal transaction partner through:

  • Synthesizing VaxTRIALS’ complex and nuanced vaccine CRO capabilities into a cohesive value proposition
  • Helping them find the right partner to accelerate their growth globally
  • Positioning their capabilities and potential synergies to maximize their value proposition


Pharma Services


Merger and Acquisition

Deal Tags

Clinical Trials
Pharma Development
International client or transaction